Market, valued at approximately USD 110.30 million in 2022, is projected to grow at a CAGR of over 6.5% from 2023 to 2030. This market focuses on the production, distribution, and utilization of ...

Dexcom's growth in sensors and U.S. expansion is solid, but slowing revenue growth and high valuation limit upside. Click ...

DexCom has barely scratched the surface of its niche in the diabetes market. Medical device specialist DexCom (NASDAQ: DXCM) ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

If you don't like the high prices that can come with popular weight-loss drugs like Ozempic-or the needle pokes they ...

While markets chase the AI hype, medtech quietly trades at decade-lows. Here’s why that’s an opportunity for long-term ...

The distribution may include a combination of ordinary dividends, capital gain, and return of investor capital, which may decrease a fund’s NAV and trading price over time.

He points out, though, that just 5% to 10% of the global population is exposed to cryptocurrency, as he notes some investors remain afraid due to past crises. That's as much of the investment advisory ...

Ethereum Price Targets $4K With Over 3.45 Million ETH Accumulation Recently Ethereum has seen strong whale accumulation, and on-chain data shows 3.45 million ETH concentrated in the $2,513 ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a Strong Buy.